However, although the expression levels of PD-L1 differed between circulating MAPS-high and MAPS-low groups, the TIDE (Tumor Immune Dysfunction and Exclusion) scores showed no difference between these two groups. This evidence concerns the gene C3orf62 and neoplasm.